Astrazeneca, Daiichi Sankyo Add Summit to Datroway Combination Push

Executive Summary

• AstraZeneca and Daiichi Sankyo have entered a clinical collaboration agreement with Summit Therapeutics to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple tumour types, including lung and breast cancers, according to AstraZeneca Press Releases.
• The companies intend to begin with a Phase III trial in first-line triple-negative breast cancer (TNBC), the statement says.
• Under the agreement, each company contributes its respective medicine for the planned combination trials, which will be sponsored by AstraZeneca or Daiichi Sankyo, with each company retaining development and commercial rights to its own medicine, per the announcement.
• AstraZeneca recently announced an equity investment that will help in part to support clinical collaborations evaluating combinations with ivonescimab, including this Datroway agreement, the company states.

Key Takeaways

• The deal adds a Datroway plus ivonescimab arm to AstraZeneca and Daiichi Sankyo's combination strategy, starting in first-line TNBC.
• Summit Therapeutics gains a route to expand ivonescimab development into breast cancer and additional solid tumour settings, per its own attributed statement.
• Trial sponsorship is split between AstraZeneca and Daiichi Sankyo, while Summit retains rights to ivonescimab and AstraZeneca and Daiichi Sankyo retain rights to Datroway.
• Ivonescimab remains a development-stage asset in most of the settings contemplated here; only certain NSCLC patients in China are approved for treatment, and a US BLA is under review rather than granted.

What the Datroway and Ivonescimab Combination Covers

The collaboration is structured around a mechanism rather than a single indication. Datroway is a TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed and commercialised by AstraZeneca and Daiichi Sankyo. Ivonescimab is a bispecific antibody that combines PD-1 blockade with anti-angiogenesis effects from VEGF blockade in a single molecule.

The stated rationale is that pairing an ADC with a next-generation immunotherapy could drive deeper, more durable responses than either approach alone. Susan Galbraith, Executive Vice President, Oncology Haematology R&D at AstraZeneca, said the company believes the combination has the potential to make a meaningful difference in multiple tumour types including lung and breast cancers. That is an attributed expectation, not a demonstrated result; no efficacy data from the planned combination is disclosed in the source material.

The first planned study is a Phase III trial in first-line TNBC. Beyond that, the source describes a multi-tumour evaluation spanning lung and breast cancers but does not enumerate a full trial roster, enrolment targets or timelines.

How the AstraZeneca Collaboration Is Structured

The commercial architecture separates contribution, sponsorship and ownership. Each company supplies its own medicine for the combination trials. Sponsorship sits with AstraZeneca or Daiichi Sankyo. All three companies contribute to trial costs, and each retains development and commercial rights to its respective medicine.

That structure differs from a licensing deal: no company is acquiring rights to another's asset, and no upfront payment or milestone schedule is disclosed in the source text. What AstraZeneca does confirm is a previously announced equity investment intended to help support clinical collaborations evaluating combinations with ivonescimab. The source names two specific uses: this Datroway agreement and a separate AstraZeneca agreement with Summit covering combinations with sonesitatug vedotin (Sone-Ve). It also refers to planned future collaborations intended to evaluate combinations with other AstraZeneca cancer medicines, including additional ADCs. The size of the equity investment and its terms are not stated in the source.

Why Summit Therapeutics Frames Ivonescimab as a Combination Partner

Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics, framed the agreement as reflecting increasing conviction in ivonescimab's potential as a foundational next-generation immunotherapy, and as advancing Summit's ambition for the drug to become the global PD-1 / VEGF partner of choice for novel combinations. She also described the Phase III study in first-line TNBC as an expansion of Summit's global development programme into breast cancer.

Related: Automotive Market Trends: Recovery, EV Share Gains, and Pricing Pressures

Those are Summit's stated ambitions. The supporting evidence in the source is a development footprint rather than commercial performance: ivonescimab is approved in China for certain patients with non-small cell lung cancer, and a Biologics License Application seeking approval in EGFR-mutated NSCLC is under review by the US Food and Drug Administration. It is being studied in Phase III trials in NSCLC, small cell lung cancer, biliary tract cancer, bladder cancer, TNBC, head and neck squamous cell carcinoma, colorectal cancer and pancreatic cancer. A BLA under review is not an approval, and the trial list indicates breadth of investigation rather than confirmed benefit in any of those settings.

Datroway's Approved Base and Development Programme

The combination work sits on top of an existing Datroway commercial and clinical footprint. The medicine is approved in more than 30 countries or regions for adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy, based on the TROPION-Breast02 trial. It is approved in more than 45 countries or regions for adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy, based on TROPION-Breast01.

It is also approved in the US and several other countries for adult patients with locally advanced or metastatic EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy, based on TROPION-Lung05 and TROPION-Lung01. The source notes that continued approval for that US indication may be contingent on verification and description of clinical benefit in a confirmatory trial.

For deeper context, see our AI analysis: "NVIDIA Signals AI Expansion with CPU Push & Groq Deal in 2026".

The broader programme includes more than 20 trials evaluating Datroway across multiple cancers including NSCLC, TNBC and urothelial cancer, with eight Phase III trials in lung cancer, five Phase III trials in breast cancer, and one Phase III plus one Phase II/III trial in urothelial cancer evaluating monotherapy and combinations. John Tsai, Global Head, R&D at Daiichi Sankyo, said the company is focused on maximising the potential of its DXd ADC portfolio through innovative combinations and strategic collaborations.

Partner and Asset Signals

The table below records only details explicitly supported by the source material. No geography beyond approving regions, and no financial terms, are disclosed.

What This Means for Practitioners

For oncology development and procurement teams, the practical signal is that combination regimens are being assembled through cost- and rights-sharing agreements rather than outright licensing. Each party keeps rights to its own medicine, so a partner's commercial position depends on trial execution, not on deal economics. Teams tracking this space should note that the first-line TNBC Phase III has not started, ivonescimab's US status is a pending BLA rather than an approval, and Datroway's NSCLC indication carries a confirmatory-trial condition in the US. Those are the near-term evidence points, not combination efficacy.

Additional coverage: Choosing Robotics AI Platforms for Enterprise Vendor Selection in 2026

AstraZeneca Implementation Risks

Three limitations are visible in the source. First, no efficacy or safety data for the Datroway and ivonescimab combination is presented; the rationale rests on mechanism and stated conviction. Second, timelines are expressed as intent, with a Phase III trial in first-line TNBC planned rather than initiated. Third, ivonescimab's regulatory position outside China is incomplete: a BLA is under review by the FDA, which is not the same as approval, and the trial list spans indications where no approval exists. Datroway's US NSCLC approval may also be contingent on confirmatory-trial verification. The source discloses no deal value, milestone structure or enrolment targets, so the financial and operational scale of this collaboration cannot be assessed from the material provided.

Editorial independence disclosure: this article was prepared by Business 2.0 News from the supplied source text without input from or review by the companies named. Source note: all factual claims are drawn from AstraZeneca Press Releases.